In oncology clinical trials, overall survival (OS) is considered the gold standard outcome measure. In phase III trials for neuroendocrine neoplasms (NENs), however, progressionfree survival (PFS) is more frequently used, as NENs are relatively rare and indolent neoplasms. But this surrogacy of PFS for OS has never been systematically validated. We, therefore, performed a literature-based analysis of phase II and III trials for NENs to evaluate the correlation between PFS and OS in NENs treated with medical treatment. We identified phase II and III clinical trials of medical treatment for advanced NENs based on a systematic electronic search using MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. A total of 20 trials were identified, and 2530 patients and 30 treatment arms were included in the analysis. There was a statistically significant relationship between PFS and OS (r s , 0.587; 95% confidence interval, 0.249-0.925). Conversely, the objective response rate was not significantly correlated with OS. The results of subgroup analyses indicated that the correlation between PFS and OS was higher for study arms that prohibited concomitant therapy with somatostatin analogues than for those that permitted it. The results of the present analysis indicate that PFS is significantly correlated with OS, and suggest that PFS is an acceptable surrogate for OS in clinical trials for NENs.
Introduction
Neuroendocrine neoplasms (NENs) are epithelial neoplasms that exhibit neuroendocrine differentiation, and they can arise from neuroendocrine cells, which are distributed widely throughout the body. NENs are relatively rare, with an estimated incidence of approximately 3.65 patients per 10,000 personyears (Lawrence et al. 2011) . However, the incidence of this neoplasm has been increasing over time (Yao et al. 2008) .
NENs are typically indolent neoplasms, but their patterns of growth and progression are variable. Yao and coworkers reported that the incidence of localized, regional, and distant NENs were 40, 19 and 21%, respectively (Yao et al. 2008) . Furthermore, NEN prognosis is highly dependent on extension behavior. Although surgical resection can sometimes result in long-term survival and even cure, (Landerholm et al. 2011 , Norton et al. 2012 its indication is limited. Metastatic disease is associated 24:9 with poorer prognosis, and median overall survival (OS) of metastatic NENs has been reported to be 12 months (Dasari et al. 2017) . In the setting of metastatic NEN, systemic therapy is indicated for control of tumor growth and disease symptoms.
Somatostatin analogues (SSAs) have long been used to control clinical symptoms caused by functioning NENs. Additionally, SSAs have been shown to prolong progression-free survival (PFS) in NEN patients (Rinke et al. 2009 . The molecular targeted drugs, sunitinib and everolimus, have also been shown to prolong PFS in NENs patients, (Pavel et al. 2011 , Raymond et al. 2011 , Yao et al. 2011 , 2016a and are widely used to control tumor growth. The survival benefit of such systemic therapeutic agents for NENs is still unclear, however, and though PFS is the most frequently used primary endpoint in phase III trials for NENs, its surrogacy for OS has never been systematically validated.
Therefore, we performed a literature-based study of prospective trials of NEN treatments to assess the validity of PFS as a surrogate for the gold standard outcome measure, OS. The primary endpoint of this study was to evaluate the correlation between PFS and OS in subjects enrolled in medical treatment clinical trials for NENs. The secondary endpoint was to explore potential correlations between other possible surrogate markers (objective response rate (ORR) and disease control ratio (DCR)) and OS.
Materials and methods

Literature search
We identified phase II and III clinical trials of medical treatment for advanced NENs published between January 1996 and December 2016, based on a systematic electronic search using MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The authors (H I and M S) independently screened each record for eligibility by examining the titles, abstracts and keywords. The search terms included 'neuroendocrine tumor', 'neuroendocrine neoplasm', 'neuroendocrine cancer', 'neuroendocrine carcinoma', or 'carcinoid'; 'drug therapy' or 'chemotherapy'; and 'clinical trial', 'controlled clinical trial', or 'randomized controlled trial'. The bibliographies of the identified articles were then screened for additional eligible articles. Among the identified articles, reports on trials including ≥20 patients per-arm were analyzed if they reported median OS and at least one surrogate endpoint. Excluded were: studies in which any arm received chemoradiotherapy, arterial infusion chemotherapy, or peptide receptor radionuclide therapy; phase I clinical trials with dose escalation design as a protocol; studies that included patients with neuroendocrine cancer defined by the WHO classification 2017. The search was limited to articles published in English.
Data collection
For each trial, the following data were extracted: first author's name; year of publication or report; trial design; medical treatment regimen; number of patients in each arm; potential surrogate markers (ORR, DCR, OS, PFS, time to progression (TTP), 6-month PFS rate, 12-month PFS rate, 12-month OS rate and biochemical response rate defined as normalization or ≥50% reduction in elevated serum chromogranin A level). In cases for which OS data were not described, data from updated reports, if available, were abstracted to complete them.
Statistical analysis
The nonparametric Spearman's rank correlation coefficient (r s ) or Pearson correlation coefficient (rp) were used to evaluate the correlations between potential surrogate markers and OS (per-arm correlation), and between treatment effects on surrogate endpoints and on OS (per-trial correlation). Furthermore, we used linear regression analysis to predict the effect of a treatment on OS based on its effect on PFS. The treatment effects on PFS and on OS were measured in terms of the differences in PFS (∆PFS), OS (∆OS), and log-transformed HRs (log HRPFS, and log HROS). Accounting for the variability of the number of trials included in each model, adjusted R 2 values were used to compare the goodness-of-fit of regression models. Values of r s and rp closer to 1 indicated a strong positive correlation between the endpoints, and those of R 2 closer to 1 indicated that the variability of OS was predominantly explained by the surrogate endpoints.
To investigate possible reasons for heterogeneity of correlation, subgroup analyses were conducted according to publication year (before 2011 vs 2011 or later), origin of the tumor (pancreas only vs extrapancreatic organs included), study design (randomized trial vs nonrandomized trial), progressive disease requirement as a protocol (required vs not required), crossover treatment (permitted vs not permitted), concomitant therapy with SSAs (allowed vs not allowed), and treatment drug type (molecular targeted drugs only vs drugs other than molecular targeted).
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Bootstrap methods with 1000 replications were applied to estimate confidence intervals (CIs) for the correlation parameters. P values <0.05 were considered statistically significant and all P values were two-sided. Data were analyzed using STATA version 14.2 statistical software (StataCorp, College Station, TX, USA).
Results
Selection of studies
A total of 20 trials (Ramanathan et al. 2001 , Kulke et al. 2004 , Arnold et al. 2005 , Sun et al. 2005 , Yao et al. 2007 , Dahan et al. 2009 , Rinke et al. 2009 , Pavel et al. 2011 , Raymond et al. 2011 , Chan et al. 2012 , Meyer et al. 2014 , Hobday et al. 2015 , Bendell et al. 2016 , Strosberg et al. 2016 ) with ≥20 patients per-arm were identified (10 randomized trials and 10 non-randomized trials), as well as four update reports (Yao et al. 2013 , 2016b , Faivre et al. 2016 , Rinke et al. 2017 ( Fig. 1 and Table 1 ). The primary endpoint of 11 trials (55%) was ORR, and that of seven trials (35%) was PFS. Fifteen trials (75%) included pancreatic neuroendocrine tumor (PNET): nine of these also included gastrointestinal neuroendocrine tumor (GINET), but six included PNET only. A total of 2530 patients and 30 treatment arms were included in the analysis. The medians of the reported median OS and PFS were 34.5 months (range, 15.7-84.7 months) and 11.0 months (range, 4.5-26.7 months), respectively. Objective RR, DCR, PFS, TTP, 12-month PFS rate and biochemical response rate were reported in 30 (100.0%), 27 (90.0%), 23 (76.7%), 8 (26.7%), 7 (23.3%) and 9 treatment arms (30.0%), respectively.
Correlation between PFS and OS (per-arm analysis)
There was a significant relationship between PFS and OS (P = 0.001). The r s value for PFS and OS was 0.587 (Fig. 2) , which corresponds to a moderate association. Results of subgroup analyses are summarized in Table 2 . The correlation between PFS and OS was higher for study arms that prohibited concomitant therapy with SSAs (r s = 0.821; P = 0.013) than for those that permitted it (r s = 0.423; P = 0.053). Moreover, analyses according to crossover treatment showed that the correlation was higher for studies that prohibited concomitant SSA therapy (r s = 0.566; P = 0.016). Correlations tended to be higher for study arms that: were in randomized trials; included 
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disease originating in extrapancreatic organs (e.g., GINET); not required progressive disease as a protocol; and included drugs other than molecular targeted drugs (e.g., cytotoxic drugs).
Correlation between the effects of treatment on PFS and OS (per-trial analysis)
For the analysis of correlations between the effects of treatment on PFS and OS, pair-wise treatment comparisons from the 10 randomized trials were analyzed as a unit. A total of eight pairs of ∆PFS/∆OS were compared, and the correlation indicated a strong association between ∆PFS and ∆OS (r s = 0.810; 95% CI, 0.411-1.208; Fig. 3 ). The regression equation was ∆OS = −7.671 (95% CI, −16.551 to 1.210) + 2.348 (95% CI, 0.347-4.348) × ∆PFS, and the adjusted R 2 was 0.509. Thus, per this model, differences in median PFS of 3, 6, 9, and 12 months corresponded to differences in median OS of −0.6, 6.4, 13.5, and 20.5 months, respectively. However, the large CI indicated the potential uncertainty due to small sample size. A total of six pairs of HRsPFS/OS were compared, but correlation between the HRPFS and HROS in each arm was negligible (rp = 0.174; 95% CI −0.865 to 1.213).
Correlation between potential surrogate markers and OS (per-arm analysis)
Correlation between potential surrogate markers and OS are summarized in Table 3 . The 12-month PFS rate showed a moderate correlation with OS (r s = 0.679; P = 0.035); ORR and DCR were not significantly correlated with OS.
Discussion
The present study shows that PFS is significantly correlated with OS for subjects in NEN medical treatment clinical trials. The PFS-related surrogate marker, 12-month PFS 
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rate, is also correlated with OS. These findings support the legitimacy of using PFS as a surrogate for OS in clinical trials for NEN therapies. We also found that ORR, which most phase II trials employ as a primary endpoint, has no correlation with OS. Use of ORR as a primary endpoint in a preliminary phase II trial could result in a potentially effective therapy being missed. Endpoints are measurable clinical and biological findings that are used for development and assessment of treatments. In oncology clinical trials, OS is considered the gold standard and it is the most commonly used primary endpoint. OS, generally defined as the span of time from study registration or randomization until death by any cause, is clinically meaningful and objectively measurable. To be informative, however, it requires long follow-up periods and a large trial population, elements that render a clinical trial both time-consuming and costly. Reliance on OS alone also delays the introduction of potentially effective therapies into clinical practice. PFS, generally defined as the time from study registration or randomization to the first of either disease progression or death from any cause, requires shorter follow-up periods and smaller sample sizes. Thus, PFS is frequently used as a surrogate endpoint for OS in oncology clinical trials. It has some important limitations, though: PFS can be affected by measurement timing, resulting in overestimation, and it may be biased by subjective assessment. Whether PFS can be accepted as a primary endpoint depends on its value as a surrogate endpoint for OS.
Surrogacy of PFS for OS has already been validated in certain types of tumors: in metastatic colorectal cancer and renal cell carcinoma, it has been shown that the effect of treatments on PFS is strongly associated with that on OS (Buyse et al. 2007 , Delea et al. 2012 . PFS has therefore been accepted as a primary endpoint in phase III trials for these cancers, (Douillard et al. 2010 , Choueiri et al. 2015 accelerating development of new chemotherapeutic agents via rapid study completion. NENs are relatively rare, and tend to exhibit indolent progression, both of which factors could complicate recruiting for, and completion of clinical trials. Thus, in clinical trials for NENs, PFS is the most commonly used endpoint. Although Ter-Minassian et al. reported the correlation between PFS and OS in patients treated with SSAs or everolimus in their single institutional retrospective study, (Ter-Minassian et al. 2017 ) the surrogacy of PFS for OS has never been systematically validated. Therefore, we performed this literature-based study of prospective trials for NENs to assess the surrogacy of PFS for OS.
Although we found the correlation between PFS and OS to be significant, the degree of correlation was modest. This could be due to various kinds of correlation heterogeneity exhibited by the clinical trials that we analyzed. To characterize and clarify this heterogeneity, we performed subgroup analyses based on several clinical perspectives. The correlation between PFS and OS was higher in subgroups that prohibited concomitant 
Differences in PFS (months) Differences in OS (months)
-
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therapy with SSAs than in subgroup that allowed it. Because SSAs improve symptoms caused by excess hormone secretion by some NENs, many studies allowed concomitant SSA therapy. Recently, SSAs have also been shown to control tumor growth in patients with NENs. Thus, SSAs obviously affect apparent NEN prognosis: concomitant therapy with SSAs may bias the estimation of treatment effect on survival. Our subgroup analysis also showed that the correlation was higher in subgroups that (1) not required progressive disease as a protocol and (2) included NENs that originated in extrapancreatic organs. The prognoses and natural histories of NENs are highly variable and several trials required documentation of disease progression as an eligibility criterion because well-differentiated NENs sometimes remain symptomfree for years, even if untreated. The prognoses of NENs may also vary depending on site of origin; Panzuto and coworkers for example, reported that PNET has a more aggressive course than GINET (Panzuto et al. 2005) . Thus, both treatment factors (concomitant therapy with SSAs) and disease factors (requirements regarding disease progression and site of origin) may contribute to heterogeneity of correlations in clinical trials for NENs. This study had some limitations. First, we relied on summary data from published trials to assess the validity of a surrogate endpoint, so individual patient data were unavailable for analysis. It has already been reported that trial-level surrogacy is not necessarily reflective of individual-level outcomes, (Berlin et al. 2002) so our data cannot be used to predict an individual's chance of survival on the basis of their response to treatment. The second limitation is the small number of prospective studies-especially randomized trials-available for NENs, a factor that likely contributes to the heterogeneity of the clinical trials. Finally, the study lacked optimal statistical power and should therefore be considered only as an exploratory investigation. Given that clinical trials for NEN treatments frequently face recruitment and completion difficulties, however, the use of PFS instead of OS in clinical trials would allow for faster development and earlier implementation of new therapeutic agents via rapid study completion.
In conclusion, the results of the present analysis indicate that PFS is significantly correlated with OS. In clinical trials for NEN therapies, the surrogacy of PFS for OS in NENs is acceptable, and PFS can be used to support development of new therapeutic agents via rapid study completion.
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